Immunotherapy, NKTR-214, Shows Activity Against Solid Tumors in Clinical Trial
News
The investigational immunotherapy NKTR-214, designed to increase tumor-killing T-cells and natural killer (NK) cells in the tumor microenvironment, may be a promising approach for a variety of solid tumors, according to ... Read more